{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360005521911427712.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1186/s40780-019-0136-4"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1186/s40780-019-0136-4.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1186/s40780-019-0136-4/fulltext.html"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2020048905"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report"}],"description":[{"notation":[{"@value":"BACKGROUND: Infliximab (IFX), a mouse-human chimeric monoclonal antibody against human tumor necrosis factor alpha, is used in refractory cases of Takayasu arteritis. Several factors influence the pharmacokinetics of therapeutic antibodies including IFX. Monitoring plasma levels of IFX could be a useful approach in optimizing treatment via individual dose adjustment. CASE PRESENTATION: Here, we report the case of a 4-year-old Takayasu arteritis girl who was resistant to standard therapy. IFX was started at 5 mg/kg (day 0). C-reactive protein (CRP) levels decreased from 8.7 (day 0) to 1.6 mg/dL (day 10). CRP levels were thereafter elevated again on day 23 (9.0 mg/dL), and body fluid leakage at the inflammation site in the legs was observed. Trough IFX levels decreased from 23.6 (day 10) to 2.5 μg/mL (day 23). Based on the trough levels, IFX was given biweekly at 8 mg/kg. Plasma IFX levels gradually increased, and CRP levels decreased to around 2 mg/dL. A similar pattern -initial decreases followed by increases- was observed between clinical course of IFX and IgG levels. It was speculated that IgG and IFX losses were due to fluid leakage from the patient’s necrotizing legs. CONCLUSIONS: Monitoring of plasma IFX levels can be a potential tool to optimize the treatment in Takayasu arteritis patients."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380005521911427584","@type":"Researcher","foaf:name":[{"@value":"Sho Masui"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276179671040","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"90452341"},{"@type":"NRID","@value":"1000090452341"},{"@type":"ORCID","@value":"0000-0002-8057-6768"},{"@type":"NRID","@value":"9000413357620"},{"@type":"NRID","@value":"9000021799778"},{"@type":"NRID","@value":"9000323844073"},{"@type":"NRID","@value":"9000314796642"},{"@type":"NRID","@value":"9000399839144"},{"@type":"NRID","@value":"9000398992845"},{"@type":"NRID","@value":"9000022700042"},{"@type":"NRID","@value":"9000389945009"},{"@type":"NRID","@value":"9000257806756"},{"@type":"NRID","@value":"9000406380017"},{"@type":"NRID","@value":"9000414748607"},{"@type":"NRID","@value":"9000415209488"},{"@type":"NRID","@value":"9000241895151"},{"@type":"NRID","@value":"9000334417646"},{"@type":"NRID","@value":"9000238323672"},{"@type":"NRID","@value":"9000415197952"},{"@type":"NRID","@value":"9000389945736"},{"@type":"NRID","@value":"9000411389989"},{"@type":"NRID","@value":"9000415428317"},{"@type":"NRID","@value":"9000412352091"},{"@type":"NRID","@value":"9000414941301"},{"@type":"NRID","@value":"9000311516793"},{"@type":"NRID","@value":"9000397646967"},{"@type":"NRID","@value":"9000369747830"},{"@type":"NRID","@value":"9000242071326"},{"@type":"NRID","@value":"9000024689887"},{"@type":"NRID","@value":"9000402501924"},{"@type":"NRID","@value":"9000415182676"},{"@type":"NRID","@value":"9000397945817"},{"@type":"NRID","@value":"9000410870783"},{"@type":"NRID","@value":"9000414941524"},{"@type":"NRID","@value":"9000272962412"},{"@type":"NRID","@value":"9000404635042"},{"@type":"NRID","@value":"9000381066491"},{"@type":"NRID","@value":"9000410148728"},{"@type":"NRID","@value":"9000279904573"},{"@type":"NRID","@value":"9000398776576"},{"@type":"NRID","@value":"9000410918778"},{"@type":"NRID","@value":"9000414385992"},{"@type":"NRID","@value":"9000257891005"},{"@type":"NRID","@value":"9000016807326"},{"@type":"NRID","@value":"9000412103940"},{"@type":"NRID","@value":"9000237858381"},{"@type":"NRID","@value":"9000327930481"},{"@type":"NRID","@value":"9000327930482"},{"@type":"NRID","@value":"9000380461645"},{"@type":"NRID","@value":"9000410317689"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/ayone"}],"foaf:name":[{"@value":"Atsushi Yonezawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326215307264","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"90634931"},{"@type":"NRID","@value":"1000090634931"},{"@type":"ORCID","@value":"0000-0003-1080-0936"},{"@type":"NRID","@value":"9000409799198"},{"@type":"NRID","@value":"9000018509185"},{"@type":"NRID","@value":"9000006807205"},{"@type":"NRID","@value":"9000240049605"},{"@type":"NRID","@value":"9000398614111"},{"@type":"NRID","@value":"9000362203192"},{"@type":"NRID","@value":"9000399604061"},{"@type":"NRID","@value":"9000410515023"},{"@type":"NRID","@value":"9000411268355"},{"@type":"NRID","@value":"9000241512115"},{"@type":"NRID","@value":"9000399803416"},{"@type":"NRID","@value":"9000398614081"},{"@type":"NRID","@value":"9000398614092"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/7000011341"}],"foaf:name":[{"@value":"Kazushi Izawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427726","@type":"Researcher","foaf:name":[{"@value":"Makoto Hayakari"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427719","@type":"Researcher","foaf:name":[{"@value":"Kayoko Asakura"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427714","@type":"Researcher","foaf:name":[{"@value":"Risa Taniguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427716","@type":"Researcher","foaf:name":[{"@value":"Masahiko Isa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427587","@type":"Researcher","foaf:name":[{"@value":"Hirofumi Shibata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427588","@type":"Researcher","foaf:name":[{"@value":"Takahiro Yasumi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427718","@type":"Researcher","foaf:name":[{"@value":"Ryuta Nishikomori"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801181688704","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00359621"},{"@type":"NRID","@value":"1000000359621"},{"@type":"ORCID","@value":"0000-0002-2452-6520"},{"@type":"NRID","@value":"9000406229976"},{"@type":"NRID","@value":"9000364866745"},{"@type":"NRID","@value":"9000326637947"},{"@type":"NRID","@value":"9000018652489"},{"@type":"NRID","@value":"9000411073337"},{"@type":"NRID","@value":"9000410487489"},{"@type":"NRID","@value":"9000402444752"},{"@type":"NRID","@value":"9000413535625"},{"@type":"NRID","@value":"9000414337544"},{"@type":"NRID","@value":"9000405107513"},{"@type":"NRID","@value":"9000018652914"},{"@type":"NRID","@value":"9000364845189"},{"@type":"NRID","@value":"9000414253859"},{"@type":"NRID","@value":"9000406229965"},{"@type":"NRID","@value":"9000412524764"},{"@type":"NRID","@value":"9000413927028"},{"@type":"NRID","@value":"9000409505533"},{"@type":"NRID","@value":"9000264271471"},{"@type":"NRID","@value":"9000298901353"},{"@type":"NRID","@value":"9000405107487"},{"@type":"NRID","@value":"9000014160914"},{"@type":"NRID","@value":"9000408577443"},{"@type":"NRID","@value":"9000405107475"},{"@type":"NRID","@value":"9000404657999"},{"@type":"NRID","@value":"9000410492891"},{"@type":"NRID","@value":"9000364871291"},{"@type":"NRID","@value":"9000329427063"},{"@type":"NRID","@value":"9000334735606"},{"@type":"NRID","@value":"9000242743880"},{"@type":"NRID","@value":"9000412182671"},{"@type":"NRID","@value":"9000364871177"},{"@type":"NRID","@value":"9000399539718"},{"@type":"NRID","@value":"9000409630231"},{"@type":"NRID","@value":"9000275827055"},{"@type":"NRID","@value":"9000364902381"},{"@type":"NRID","@value":"9000413515063"},{"@type":"NRID","@value":"9000364907103"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/jt-kyoto"}],"foaf:name":[{"@value":"Junko Takita"}]},{"@id":"https://cir.nii.ac.jp/crid/1380005521911427721","@type":"Researcher","foaf:name":[{"@value":"Kazuo Matsubara"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"20550294"}],"prism:publicationName":[{"@value":"Journal of Pharmaceutical Health Care and Sciences"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2019-05-02","prism:volume":"5","prism:number":"1","prism:startingPage":"9"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://creativecommons.org/licenses/by/4.0/","http://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1186/s40780-019-0136-4.pdf"},{"@id":"http://link.springer.com/article/10.1186/s40780-019-0136-4/fulltext.html"},{"@id":"https://search.jamas.or.jp/link/ui/2020048905"}],"createdAt":"2019-05-02","modifiedAt":"2020-05-15","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=RS1-441","dc:title":"RS1-441"},{"@id":"https://cir.nii.ac.jp/all?q=Pharmacy%20and%20materia%20medica","dc:title":"Pharmacy and materia medica"},{"@id":"https://cir.nii.ac.jp/all?q=Pharmacokinetics","dc:title":"Pharmacokinetics"},{"@id":"https://cir.nii.ac.jp/all?q=Case%20Report","dc:title":"Case Report"},{"@id":"https://cir.nii.ac.jp/all?q=Therapeutics.%20Pharmacology","dc:title":"Therapeutics. Pharmacology"},{"@id":"https://cir.nii.ac.jp/all?q=RM1-950","dc:title":"RM1-950"},{"@id":"https://cir.nii.ac.jp/all?q=LC-MS/MS","dc:title":"LC-MS/MS"},{"@id":"https://cir.nii.ac.jp/all?q=Infliximab","dc:title":"Infliximab"},{"@id":"https://cir.nii.ac.jp/all?q=Takayasu%20arteritis","dc:title":"Takayasu arteritis"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781957593728","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17H04224"},{"@type":"JGN","@value":"JP17H04224"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17H04224/"}],"notation":[{"@language":"ja","@value":"マルチオミックス情報を基盤とした難治性小児がんに対する新規克服法の開発"},{"@language":"en","@value":"Development of novel therapeutic strategies for intractable pediatric cancers based on the multi-omics information"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000782014668160","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"19H03389"},{"@type":"JGN","@value":"JP19H03389"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19H03389/"}],"notation":[{"@language":"ja","@value":"抗体医薬品に対する抗薬物抗体の実態解明と臨床疫学解析"},{"@language":"en","@value":"Basic and clinical analysis of anti-drug antibody against therapeutic antibody"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000782023251968","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"19K17293"},{"@type":"JGN","@value":"JP19K17293"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K17293/"}],"notation":[{"@language":"ja","@value":"NLRP3、NLRC4疾患関連変異によるカスパーゼ1非依存性細胞死の機序解明"},{"@language":"en","@value":"Mechanisms of caspase-1-independent cell death induced by NLRP3 and NLRC4 disease-associated variants"}]},{"@id":"https://cir.nii.ac.jp/crid/1040282256982891136","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18K19467"},{"@type":"JGN","@value":"JP18K19467"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K19467/"}],"notation":[{"@language":"ja","@value":"小児がんと神経発達のクロストークの解明と新規治療法の開発"},{"@language":"en","@value":"Elucidation of crosstalk between pediatric cancers and neural development and its application for novel therapeutic strategies"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360282588968032384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705563249280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519419600512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520035638656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994340159488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Monitoring serum concentration of infliximab might improve RA disease control"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996286259072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469796644864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943884112512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945414524672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418371686528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896205262720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793610157056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti TNF-α in refractory Takayasu's arteritis: Cases series and review of the literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270943766272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205104175232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guideline for Management of Vasculitis Syndrome (JCS 2008)"},{"@value":"Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -"},{"@value":"Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1186/s40780-019-0136-4"},{"@type":"KAKEN","@value":"PRODUCT-22934460"},{"@type":"KAKEN","@value":"PRODUCT-22803826"},{"@type":"KAKEN","@value":"PRODUCT-22977962"},{"@type":"KAKEN","@value":"PRODUCT-23082497"},{"@type":"OPENAIRE","@value":"doi_dedup___::68ce37efee635a7c693888980032b2bc"},{"@type":"CROSSREF","@value":"10.1039/d2an01032a_references_DOI_ZWyKwi6jz5muFYdf1nnCzpVmCsh"}]}